Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
Background & Aims Many patients with inflammatory bowel disease (IBD) fail to respond to anti–tumor necrosis factor (TNF) agents such as infliximab and adalimumab, and etanercept is not effective for treatment of Crohn’s disease. Activated matrix metalloproteinase 3 (MMP3) and MMP12, which are i...
Saved in:
Published in | Gastroenterology (New York, N.Y. 1943) Vol. 149; no. 6; pp. 1564 - 1574.e3 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.11.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!